Abstract:Immunogenic cell death (ICD), which converts tumor cells into their own vaccine, plays a pivotal role in the development of novel anti-cancer therapies. Here, a small series of osmium(II) polypyridyl complexes were synthesized and their biological activity in the dark and upon light irradiation against various cancer cell lines was studied. The compound Os2 (bearing two 4,7-diphenyl-1,10-phenanthrolines and one substituted bipyridine ligand) was discovered to be the most effective photosensitizer (PS) for photodynamic therapy (PDT) of this series through the photogeneration of 1O2 and •OH. In addition, Os2 was found to exhibit promising toxicity upon near-infrared (NIR) irradiation under both normoxia and hypoxia. These observations indicate that this PS is working through a mixture of Type-I and Type-II mechanisms. More interestingly, upon 740 nm irradiation, Os2 can stimulate a strong ICD response both in vitro and in vivo. A comprehensive immune analysis showed that mice vaccinated with Os2-treated CT26-luc cells boosted the systemic specific adaptive immune responses, including the activation of CD8+ T cells and reprograming of macrophages, leading to effective inhibition of tumor growth. Os2 is, to the best of our knowledge, the first photoactive osmium-based complex inducing ICD.

What problem does this paper attempt to address?

The key problem that this paper attempts to solve is how to develop a new photosensitizer capable of inducing immunogenic cell death (ICD) for use in photodynamic therapy (PDT). Specifically, the focus of the research is to synthesize and characterize a series of osmium(II) polypyridine complexes and evaluate their biological activities and toxicities against multiple cancer cell lines under different wavelengths of light. ### Main problems: 1. **Developing new photosensitizers**: The research aims to develop an osmium(II) - based near - infrared - absorbing photosensitizer that can effectively induce immunogenic cell death under light conditions. 2. **Verifying its ability to induce ICD**: Through in vitro and in vivo experiments, verify whether Os2 can effectively induce immunogenic cell death and explore its mechanism of action. 3. **Exploring its potential for clinical application**: Study the phototoxicity and selectivity of Os2 under different conditions, as well as its stability in the tumor microenvironment, to provide a basis for possible future clinical applications. ### Specific objectives: - Synthesize and characterize three osmium(II) polypyridine complexes (Os1, Os2, Os3), especially Os2. - Study the cytotoxicity of these complexes in the dark and under light conditions, especially the selective toxicity to cancer cells. - Evaluate the phototoxicity and stability of Os2 under different wavelengths of light. - Verify whether Os2 can induce ICD by generating singlet oxygen (\(^1O_2\)) and hydroxyl radicals (\(\cdot OH\)). - Explore the immune response of Os2 in in vivo experiments, including activating CD8+ T cells and reprogramming macrophages. ### Research background: Immunogenic cell death (ICD) is a special form of cell death that can transform tumor cells into their own vaccines, thereby stimulating the adaptive immune response. In recent years, photodynamic therapy (PDT) has shown great potential in inducing ICD as a treatment method with high spatiotemporal selectivity and non - invasiveness. However, most current photosensitizers mainly focus on organic compounds or transition - metal complexes, and osmium(II) - based photosensitizers have not been reported yet. Through this research, the author hopes to fill this gap and provide a reference for the development of new and efficient ICD inducers.

A Near-Infrared-Absorbing Osmium(II) Complex as a Photosensitizer for Photodynamic Therapy inducing Immunogenic Cell Death

Metalloporphyrin–indomethacin conjugates as new photosensitizers for photodynamic therapy

Novel Naphthalimide Bridged Zinc Porphyrin/bodipy Nanomaterials with D-A Structure for Photodynamic Therapy

Photoactivated Osmium Arene Anticancer Complexes

Near-infrared photodynamic and photothermal co-therapy based on organic small molecular dyes

A near-infrared light-activatable Ru(II)-coumarin photosensitizer active under hypoxic conditions

Photostable Iridium(III) Cyclometallated Complex is an Efficient Photosensitizer for Killing Multiple Cancer Cell Lines and 3D Models under Low Doses of Visible Light

A mitochondria-localized iridium(III) photosensitizer for two-photon photodynamic immunotherapy against melanoma

Rational design of iridium-porphyrin conjugates for novel synergistic photodynamic and photothermal therapy anticancer agents

Highly Efficient Photosensitizers with Molecular Vibrational Torsion for Cancer Photodynamic Therapy

BODIPY-based Monofunctional Pt (II) Complexes for Specific Photocytotoxicity Against Cancer Cells

Rationally designed near-infrared AIEgens photosensitizer for cell membrane-targeted photo-driven theranostics

Precise ligand engineering of Ir(III)-based photosensitizer with aggregation-induced emission for image-guided photodynamic therapy

In Vivo-assembled phthalocyanine/albumin supramolecular complexes combined with a hypoxia-activated prodrug for enhanced photodynamic immunotherapy of cancer

Type I photodynamic therapy with a self-degradable conjugated polyelectrolyte in combination with CpG adjuvant for cancer immunotherapy

Photosensitizer-Singlet Oxygen Sensor Conjugated Silica Nanoparticles for Photodynamic Therapy and Bioimaging

Transition metal complexes as photosensitizers for integrated cancer theranostic applications

A NIR‐Light‐Activated and Lysosomal‐Targeted Pt (II) Metallacycle for Highly Potent Evoking of Immunogenic Cell Death that Potentiates Cancer Immunotherapy of Deep‐Seated Tumors

Rational Design of Near-Infrared-Absorbing Pt(II)-Chelated Azadipyrromethene Dyes as a New Generation of Photosensitizers for Synergistic Phototherapy

The biological activities of 5,15-diaryl-10,20-dihalogeno porphyrins for photodynamic therapy

Novel diketopyrrolopyrrole NIR-II fluorophores and DDR inhibitors for in vivo chemo-photodynamic therapy of osteosarcoma